{"product_id":"global-pompe-disease-treatment-market-research-report-forecast-to-2030","title":"Global Pompe Disease Treatment Market Research Report Forecast to 2030","description":"\u003cp\u003eGlobal Pompe Disease Treatment Market Research Report Forecast to 2030\u003c\/p\u003e\n\n\u003cp\u003ePompe disease treatment, Market Forecast till 2030\u003c\/p\u003e\n\n\u003cp\u003eMarket Overview\u003cbr\u003e\nThe global market for pompe disease treatment is expected to increase at a large over the forecast period of 2022-2030. This is a rare and fatal disorder that causes degeneration of brain cells, leading to tremors, seizures, and cognitive impairment. The treatment market for Pompe disease has been growing in recent years, with a prevalence of about 1 in 200,000 people in the USA and an annual incidence rate of about 1 case per 800,000 people. The treatment market includes both direct-to-consumer options such as stem cell transplantation, bone marrow transplantation, chemotherapy, and immunotherapy, as well as healthcare providers such as academic medical centers and private practices.\u003cbr\u003e\nThe market for Pompe disease treatment is expected to grow in the coming years due to the increasing prevalence of the disease, and the availability of new treatment options. The growing awareness about the disease and the availability of new therapies, such as enzyme replacement therapy (ERT), is also expected to drive the market growth.\u003cbr\u003e\nERT is the most commonly used treatment for Pompe disease and is considered to be the standard of care. However, there are also other treatment options available, such as gene therapy and substrate reduction therapy (SRT). These treatments are still in the early stages of development, but are showing promising results in clinical trials.\u003cbr\u003e\n The Pompe disease treatment is expected to benefit from rising number of clinical trials for new therapies. This is expected to lead to the development of more effective treatments for the disease in the future.\u003cbr\u003e\nOverall, the market for Pompe disease treatment is expected to grow in the coming years due to the increasing prevalence of the disease, the availability of new treatment options, and the growing awareness about the disease.\u003cbr\u003e\nThe market is also driven by the increasing number of patients being diagnosed with Pompe disease, and the growing number of clinical trials for new therapies. This is expected to lead to the development of more effective treatments for the disease in the future.\u003cbr\u003e\nSegment Overview\u003cbr\u003e\nThe Type, treatment type, end user, and regional segmentation have been used to segment the market of the global Pompe Disease treatment market. The market has been segmented into three main categories based on the type of Pompe disease: Non-Classic Infantile-Onset Pompe Disease, Late-Onset Pompe Disease, and Classic Infantile-Onset Pompe Disease. The Therapy type segment has been split The Treatment Types section has been divided into Gene Therapy, Enzyme Replacement Therapy, and Others.urcated into Research and Academic Institutes, Hospitals and Clinics\u003cbr\u003e\nRegional Analysis\u003cbr\u003e\nNorth America is expected to dominate the market and hold the major share due to the presence of advanced healthcare infrastructure and the high prevalence of Pompe disease in the region. The availability of reimbursement policies, increased awareness about Pompe disease, and the presence of major market players in the region also contribute to the market growth in North America. \u003cbr\u003e\nIn Europe, countries such as Italy, Germany, and France are expected to show a significant progress due to the increasing prevalence of the disease and the availability of advanced healthcare infrastructure. \u003cbr\u003e\nMajor Players\u003cbr\u003e\nOxyrane (UK), Valerion Therapeutics (US), AVROBIO, Inc. (US), Audentes Therapeutics (US), Amicus Therapeutics, Inc (US), Sanofi (France), CENTOGENE AG (UK) are some of the affluent contenders holding sizeable pompe disease treatment market share. \u003cbr\u003e\nCOVID 19 Impacts\u003cbr\u003e\nThe pandemic caused by COVID-19 has affected the supply chain and the production of medical products for Pompe disease. The market may face disruption due to a lack of attendance of human labour at work and in factories. However, there is a silver lining. Just like any other market, advanced technology has taken place instead of human labour. Though it may need human interventions from time to time, it is indeed scarce. The government of various nations are running vaccine drives. The initial months of the COVID-19 pandemic saw a decline in production of the market. However, the Pompe Disease Treatment Market has paced up production.\u003c\/p\u003e\n\n\n\u003cp\u003eCompanies Mentioned\u003cbr\u003e\nOxyrane (UK)\u003cbr\u003e\nValerion Therapeutics (US)\u003cbr\u003e\nAVROBIO\u003cbr\u003e\nInc. (US)\u003cbr\u003e\nAudentes Therapeutics (US)\u003cbr\u003e\nAmicus Therapeutics\u003cbr\u003e\nInc (US)\u003cbr\u003e\nSanofi (France)\u003cbr\u003e\nCENTOGENE AG (UK)\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"April, 2023 \/ 123 Pages \/ MCW16229551","offer_id":47646968578354,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-pompe-disease-treatment-market-research-report-forecast-to-2030","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}